Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity

We have previously shown that the addition of the raltegravir/elvitegavir (RAL/EVG) primary resistance mutation N155H to the R263K dolutegravir (DTG) resistance mutation partially compensated for the fitness cost imposed by R263K while also slightly increasing DTG resistance in vitro (K. Anstett, T....

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Virol
Autores principales: Anstett, Kaitlin, Fusco, Robert, Cutillas, Vincent, Mesplède, Thibault, Wainberg, Mark A.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Microbiology 2015
Materias:
Vaccines and Antiviral Agents
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4580168/
https://ncbi.nlm.nih.gov/pubmed/26246578
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.01725-15
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares